Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$1.82 AUD
Change Today -0.06 / -3.19%
Volume 28.8K
MVP On Other Exchanges
Symbol
Exchange
Berlin
As of 1:34 AM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

medical developments interna (MVP) Snapshot

Open
A$1.89
Previous Close
A$1.88
Day High
A$1.90
Day Low
A$1.82
52 Week High
03/9/15 - A$2.54
52 Week Low
09/10/14 - A$1.02
Market Cap
105.1M
Average Volume 10 Days
56.2K
EPS TTM
A$0.02
Shares Outstanding
57.7M
EX-Date
09/2/13
P/E TM
85.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDICAL DEVELOPMENTS INTERNA (MVP)

Related News

No related news articles were found.

medical developments interna (MVP) Related Businessweek News

No Related Businessweek News Found

medical developments interna (MVP) Details

Medical Developments International Limited manufactures and distributes pharmaceutical drugs, and medical and veterinary equipment in Australia, New Zealand, Eastern Europe, Germany, Canada, the Middle East, and South America. The company offers Penthrox, a non-narcotic inhaled analgesic that is self-administered by conscious haemodynamically stable patients through the hand-held inhaler to provide emergency or procedural related pain relief. It also provides asthma and COPD medical devices comprising space chambers, breath-alert peak flow meters for adult and children, and disposable face mask, as well as silicone face mask for adult and children; and finger pulse oximeter, and portable nebulizer products. In addition, the company offers rescue and resuscitation products; veterinary equipment, including rota flush, anesthetic machines, breath–alert, KAB autoclavable bar and nipple attachments, in circuit vaporizers, Easyfill systems, and KDK flowmeters; and automated external defibrillators. It sells its products through a network of industry specific distributors. The company is headquartered in Springvale, Australia.

26 Employees
Last Reported Date: 08/21/14

medical developments interna (MVP) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: A$276.0K
Company Secretary and Group Financial Control...
Total Annual Compensation: A$10.7K
Finance Manager
Total Annual Compensation: A$49.6K
Compensation as of Fiscal Year 2014.

medical developments interna (MVP) Key Developments

Medical Developments International Limited Appoints Philip Powell as a Non-Executive Director

Medical Developments International Limited announced the appointment of Mr. Philip Powell as a non-executive Director of the Company with immediate effect. From January 2006 to July 2013 Philip was an Executive Director at Corporate Finance Advisory firm Kidder Williams.

Medical Developments International Limited, Annual General Meeting, Oct 28, 2014

Medical Developments International Limited, Annual General Meeting, Oct 28, 2014., at 10:30 AUS Eastern Standard Time. Location: Level 10, Deloitte Touche Tohmatsu. Agenda: To consider the remuneration report; to consider the re-election of director - Dr. Harry Oxer; and to consider the election of director - Mr. Leon Hoare.

Galen Inks Deal with Medical Developments International

Galen reported a significant deal with Medical Developments International. The company noted that the long term licensing agreement enables Galen to exclusively market, distribute, and supply MVP 's emergency pain relief product, Penthrox, throughout the UK and Ireland and signifies the next step in building a specialty products' portfolio in Europe. Penthrox is a rapid onset, non-narcotic, inhaled analgesic that may be self-administered by conscious patients with pain resulting from trauma injuries, under the direction of emergency healthcare professionals, via a hand-held inhaler. MVP estimate the emergency market in the UK for Penthrox could be up to 5 times that of the Australian market and therefore represents a substantial opportunity for both companies involved.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MVP:AU A$1.82 AUD -0.06

MVP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MVP.
View Industry Companies
 

Industry Analysis

MVP

Industry Average

Valuation MVP Industry Range
Price/Earnings 87.9x
Price/Sales 10.0x
Price/Book 6.2x
Price/Cash Flow 88.0x
TEV/Sales 9.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDICAL DEVELOPMENTS INTERNA, please visit www.medicaldev.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.